个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Lin Kong-Ying[1,2] * ; Liu Hong-Zhi[1] * ; Liu Jian-Wei[3] * ; Zhu Xiao-Dong[4] * ; Pan Yang-Xun[5] ; Shen Shun-Li[6] ; Zhang Wei[7] ; Jin Ren-An[8] ; Han Chuang-Ye[9] ; Chen Jie[10] ; Zhang Xiao-Yun[11] ; Liang Bin-Yong[12] ; Zhang Yao-Dong[13] ; Ma Jian[14] ; Wang Nan-Ya[15] ; Li Dong-Xiao[16] ; Xiong Rui[17] ; Li Zhong-Chao[18] ; Li Jing-Dong[19] ; Zhang Zhi-Bo[20] ; Chen Jin-Hong[21] ; Chen Yu-Feng[22] ; Zheng Lu[23] ; Zhao Lei[18] ; Yin Tao[17] ; Li De-Yu[16] ; Zhang Lei[14] ; Li Xiang-Cheng[13] ; Huang Zhi-Yong[12] ; Wen Tian-Fu[11] ; Chen Ya-Jin[10] ; Peng Tao[9] ; Liang Xiao[8] ; Song Tian-Qiang[7] ; Kuang Ming[6] ; Xu Li[5] ; Wang Kui[3] ; Sun Hui-Chuan[4] ; Zeng Yong-Yi[1,2,20] ;
机构： [1]Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350000, China [2]Fujian Provincial Liver Disease Research Center, Fuzhou, 350001, China. [3]Department of Hepatobiliary Surgery, The Third Affiliated Hospital (Eastern Hepatobiliary Surgery Hospital), Naval Medical University, Shanghai, 200433, China. [4]Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. [5]Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, 510060, China. [6]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China. [7]Department of Hepatobiliary Surgery, National Clinical Research Center of Cancer, Oncology Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. [8]Department of General Surgery, Sir Run Run Shaw Hospital, College of Medicine, Institute of Minimally Invasive Surgery, Zhejiang University, Hangzhou, 310016, China. [9]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530012, China. [10]Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China. [11]Department of Hepatobiliary Surgery, West China Hospital, Sichuan University, Chengdu, 610041, China. [12]Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. [13]Department of Hepatobiliary Surgery, Jiangsu Province Hospital, Nanjing, 210029, China. [14]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Lanzhou University, Lanzhou, 730000, China. [15]Tumor Center, The First Hospital of Jilin University, Changchun, 130012, China. [16]Department of Gastroenterology, Henan University People's Hospital, Zhengzhou, 450003, China. [17]Department of Hepatobiliary and Pancreatic Surgery, Hubei Cancer Hospital, Wuhan, 430079, China. [18]Department of Hepatobiliary Surgery, Affiliated Cancer Hospital, Shandong First Medical University, Jinan, 250117, China. [19]Department of Hepatobiliary Surgery, Affiliated Hospital, North Sichuan Medical College, Sichuan, 637000, China. [20]Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China. [21]Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, China. [22]Department of General Surgery, Zhangzhou Affiliated Hospital, Fujian Medical University, Zhangzhou, 363000, China. [23]Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Army Medical University, Chongqing, 400016, China.
出处：
DOI： 10.1016/j.ejso.2025.110220
ISSN：

关键词： Conversion therapy Early recurrence Hepatocellular carcinoma Resection Risk score

摘要：
Conversion therapy with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) offers the potential for curative resection in unresectable hepatocellular carcinoma (HCC). However, early recurrence (≤2 years) after conversion liver resection remains a major concern. This study aimed to develop and validate online preoperative and postoperative risk scores to predict early recurrence in patients undergoing conversion liver resection.A total of 203 patients with initially unresectable HCC who underwent conversion liver resection following TKI and ICI therapy across 28 academic centers were analyzed. Independent predictors of early recurrence were identified using Cox proportional hazards analyses, and risk scores were developed and validated using the C-index, time-dependent AUC (tdAUC), and calibration curves.Preoperative risk score model included the neutrophil-to-lymphocyte ratio (NLR) ≥ 1.39, multiple tumors, absence of radiographic response, and no alpha-fetoprotein (AFP) response. Postoperative risk score model included NLR ≥1.39, multiple tumors, no AFP response, active macrovascular invasion, and incomplete pathological response. The preoperative risk score had a C-index of 0.699 (training) and 0.681 (validation), while the postoperative risk score had a C-index of 0.739 (training) and 0.706 (validation). Both models demonstrated good predictive accuracy through tdAUC and calibration curves. Decision tree analysis stratified patients into distinct risk categories with significant differences in 2-year recurrence rates. All risk score models are available online for clinical use.Online preoperative and postoperative risk scores provide valuable tools for predicting early recurrence in HCC patients after conversion liver resection, aiding in surgical decision-making and postoperative management.Copyright © 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

基金：
This study was supported by the National Key Research and Development Plan (Grant number: 2022YFC2407304), the Major Scientific Research Project for Young and Middle-Aged People of the Fujian Provincial Health Commission (Grant number: 2021ZQNZD013), the Scientific Foundation of the Fuzhou Municipal Health Commission (Grant number: 2021-S-wp1), and the Fujian Medical University Qihang Fund Graduate Innovation Project (Grant number: 2022QH2030).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学 2 区 外科
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学 2 区 外科
JCR分区：
出版当年[2024]版：
Q1 SURGERY Q2 ONCOLOGY
最新[2024]版：
Q1 SURGERY Q2 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2024版]

第一作者：
第一作者机构： [1]Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350000, China [2]Fujian Provincial Liver Disease Research Center, Fuzhou, 350001, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350000, China [2]Fujian Provincial Liver Disease Research Center, Fuzhou, 350001, China. [20]Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.
推荐引用方式(GB/T 7714)：
Lin Kong-Ying,Liu Hong-Zhi,Liu Jian-Wei,et al.Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy[J].European Journal Of Surgical Oncology : The Journal Of The European Society Of Surgical Oncology And The British Association Of Surgical Oncology.2025,51(9):110220.doi:10.1016/j.ejso.2025.110220.
APA：
Lin Kong-Ying,Liu Hong-Zhi,Liu Jian-Wei,Zhu Xiao-Dong,Pan Yang-Xun...&Zeng Yong-Yi.(2025).Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy.European Journal Of Surgical Oncology : The Journal Of The European Society Of Surgical Oncology And The British Association Of Surgical Oncology,51,(9)
MLA：
Lin Kong-Ying,et al."Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy".European Journal Of Surgical Oncology : The Journal Of The European Society Of Surgical Oncology And The British Association Of Surgical Oncology 51..9(2025):110220

相关文献

[1]Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study [2]Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC [3]Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition) [4]Cancer Genomic Alterations Can Be Potential Biomarkers Predicting Microvascular Invasion and Early Recurrence of Hepatocellular Carcinoma. [5]Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study [6]Recurrence in Early-Stage Hepatocellular Carcinoma: CpG Methylation and Smoking Reply [7]CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study [8]Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study [9]Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy [10]Nomogram for predicting early cancer-related death due to recurrence after liver resection in hepatocellular carcinoma patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C: a multicenter study

资源点击量：65768 今日访问量：2 总访问量：5150 更新日期：2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号